Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase - Implication for atherosclerosis
| dc.contributor.author | Eisaf, M. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.date.accessioned | 2015-11-24T16:56:53Z | |
| dc.date.available | 2015-11-24T16:56:53Z | |
| dc.identifier.issn | 0006-2952 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/10502 | |
| dc.rights | Default Licence | - |
| dc.subject | atherosclerosis | en |
| dc.subject | dyslipidemia | en |
| dc.subject | lipoproteins | en |
| dc.subject | paf-acetylhydrolase | en |
| dc.subject | atorvastatin | en |
| dc.subject | fenofibrate | en |
| dc.subject | low-density-lipoprotein | en |
| dc.subject | human-plasma | en |
| dc.subject | paf-ah | en |
| dc.subject | disease | en |
| dc.subject | ldl | en |
| dc.subject | hdl | en |
| dc.subject | hypercholesterolemia | en |
| dc.subject | metabolism | en |
| dc.subject | enzyme | en |
| dc.subject | risk | en |
| dc.title | Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase - Implication for atherosclerosis | en |
| heal.abstract | Human plasma platelet activating factor acetylhydrolase (PAF-AH) is an enzyme associated mainly with the apolipoprotein B (apoB)containing lipoproteins and primarily with low-density lipoprotein (LDL). A small proportion of enzyme activity is also associated with high-density lipoprotein (HDL). PAF-AH activity is essential for the metabolism of PAF and oxidized phospholipids, i.e. bioactive lipids that are involved in the pathophysiology of atherosclerosis. Thus, PAF-AH may play a significant role in atherogenesis. Accumulating data indicate that PAF-AH associated with HDL particles plays a predominantly antiatherogenic role. By contrast, the role of LDL-associated PAF-AH remains controversial. Dyslipidemia induces a significant increase in total plasma PAF-AH activity and alters the enzyme distribution between proatherogenic apoB- and antiatherogenic apo AI-containing lipoproteins by increasing the PAF-AH activity associated with apoB-containing lipoproteins. The decreased rate of LDL removal from the circulation and the abnormal catabolism of triglyceride-rich lipoproteins play important roles in these abnormalities. Atorvastatin or fenofibrate therapy can restore, at least partially, the dyslipidemia-induced alterations in plasma PAF-AH by increasing the ratio of HDL-PAF-AH to plasma PAF-AH (or to LDL-cholesterol) levels, which may represent an important antiatherogenic effect of these hypolipidemic drugs. (C) 2003 Elsevier Inc. All rights reserved. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | Doi 10.1016/S0006-2952(03)00559-8 | - |
| heal.identifier.secondary | <Go to ISI>://000186847300001 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0006295203005598/1-s2.0-S0006295203005598-main.pdf?_tid=b0967c297efdd9a5dc460807a4421110&acdnat=1333111080_92805e71abf41d0f95f3a7e1b3774a9d | - |
| heal.journalName | Biochem Pharmacol | en |
| heal.journalType | peer reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2003 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: